268
Participants
Start Date
March 20, 2019
Primary Completion Date
October 14, 2020
Study Completion Date
October 14, 2020
Ceftolozane/Tazobactam
Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.
Metronidazole
Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
Meropenem
Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
Placebo
Saline by IV infusion every 8 hours for 4 to 14 days.
Navy General Hospital ( Site 0009), Beijing
Peking University Third Hospital ( Site 0002), Beijing
The Second Hospital of Jilin University ( Site 0048), Changchun
Zhongshan Hospital of Fudan University ( Site 0001), Shanghai
Subei People's Hospital ( Site 0046), Yangzhou
Shanghai General Hospital ( Site 0016), Shanghai
Central Hospital of Minhang District ( Site 0052), Shanghai
Affiliated Hospital of Jiangsu University ( Site 0049), Zhenjiang
The First People's Hospital of Changzhou ( Site 0054), Changzhou
Wuxi No.2 People's Hospital ( Site 0050), Wuxi
Wuxi People's Hospital ( Site 0020), Wuxi
Anhui Provincial Hospital ( Site 0033), Hefei
Liaocheng People s hospital ( Site 0014), Liaocheng
Tianjin People's Hospital ( Site 0040), Tianjin
Taizhou Hospital of Zhejiang Province ( Site 0035), Taizhou
The 2nd Affiliated Hospital of Wenzhou Medical University ( Site 0051), Wenzhou
The First Affiliated Hospital of Wenzhou Medical University ( Site 0015), Wenzhou
The First Affiliated Hospital of Nanchang University ( Site 0029), Nanchang
The Second Affiliated Hospital of Nanchang University ( Site 0053), Nanchang
The First Affiliated Hospital of Guangzhou Medical University ( Site 0026), Guangzhou
Southern Medical University Nanfang Hospital ( Site 0055), Guangzhou
Hainan General Hospital ( Site 0042), Haikou
The First Hospital of Kunming ( Site 0041), Kunming
The First Affiliated Hospital of Xinjiang Medical University ( Site 0034), Ürümqi
Baotou Central Hospital ( Site 0013), Baotou
Merck Sharp & Dohme LLC
INDUSTRY